866-997-4948(US-Canada Toll Free)

Seborrhea - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2009

Category :

Pharmaceutical

No. of Pages : 39 Pages

Seborrhea - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea Pipeline Review, H1 2017, provides an overview of the Seborrhea (Dermatology) pipeline landscape.

Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Seborrhea Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Seborrhea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 2, 2 and 2 respectively.

Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Seborrhea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Seborrhea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Seborrhea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Seborrhea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Seborrhea (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Seborrhea (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Seborrhea (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Seborrhea - Overview
Seborrhea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Seborrhea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Seborrhea - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Amorepacific Corp
Biomar Microbial Technologies
EpiPharm AG
Phosphagenics Ltd
Vyome Biosciences Pvt Ltd
Seborrhea - Drug Profiles
artemether - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-07A081 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-07A085 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Seborrhea - Dormant Projects
Seborrhea - Discontinued Products
Seborrhea - Product Development Milestones
Featured News & Press Releases
Feb 27, 2017: Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis - a Common Skin Condition
Nov 15, 2016: Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition
Oct 19, 2016: New Observational Study Demonstrates Patient Impact of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans
Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs
Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis
Mar 17, 2015: Aclaris Therapeutics Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor
Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor
Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Seborrhea, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Seborrhea - Pipeline by Aclaris Therapeutics Inc, H1 2017
Seborrhea - Pipeline by Amorepacific Corp, H1 2017
Seborrhea - Pipeline by Biomar Microbial Technologies, H1 2017
Seborrhea - Pipeline by EpiPharm AG, H1 2017
Seborrhea - Pipeline by Phosphagenics Ltd, H1 2017
Seborrhea - Pipeline by Vyome Biosciences Pvt Ltd, H1 2017
Seborrhea - Dormant Projects, H1 2017
Seborrhea - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Seborrhea, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *